Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 27, 2020
Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcomeEleni Karatza, Sophia L Markantonis, Andria Savvidou, et al.
Materials (Basel, Switzerland)|August 25, 2019
In Vivo Evaluation of the Anti-Inflammatory Activity of Electrospun Micro/Nanofibrous Patches Loaded with Pinus halepensis Bark Extract on Hairless Mice SkinEleftheria Kotroni, Eleftheria Simirioti, Stefanos Kikionis, et al.
Life (Basel, Switzerland)|October 23, 2021
Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy IndividualsEvangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, et al.
Marine Drugs|September 22, 2022
Ulvan-Based Nanofibrous Patches Enhance Wound Healing of Skin Trauma Resulting from Cryosurgical Treatment of KeloidsStefanos Kikionis, Marianna Koromvoki, Anna Tagka, et al.
Vaccines|August 6, 2021
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic EventsEvangelos Terpos, Marianna Politou, Ioannis Ntanasis-Stathopoulos, et al.
Cancers|June 2, 2021
Management of Acute Radiodermatitis in Non-Melanoma Skin Cancer Patients Using Electrospun Nanofibrous Patches Loaded with Pinus halepensis Bark ExtractAikaterini Kyritsi, Stefanos Kikionis, Anna Tagka, et al.
Drug Research|July 21, 2017
In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II)Marilena Vlachou, Angeliki Siamidi, Dimitrios Spaneas, et al.
The American Journal of Medicine|August 20, 2021
Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular DiseasePhilip C Robinson, Robert Terkeltaub, Michael H Pillinger, et al.
American Journal of Hematology|July 24, 2022
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignanciesEvangelos Terpos, Despina Fotiou, Vangelis Karalis, et al.
Biomedicines|February 25, 2022
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, et al.
Pageof 7